Black Rock Inc. Immatics N.V. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Immatics N.V. stock. As of the latest transaction made, Black Rock Inc. holds 690,761 shares of IMTX stock, worth $3.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

690,761

Previous 658,390 4.92%

Holding current value

$3.45 Million

Previous $6.92 Million 16.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$9.78 - $13.49 $316,588 - $436,684	32,371 Added 4.92%	690,761 $8.03 Million
Q1 2024 May 10, 2024	BUY	$10.23 - $12.94 $6.35 Million - $8.03 Million	620,523 Added 1638.69%	658,390 $6.92 Million
Q4 2023 Feb 13, 2024	BUY	$7.36 - $10.89 $56,605 - $83,754	7,691 Added 25.49%	37,867 $398,000
Q3 2023 Nov 13, 2023	BUY	$11.01 - $12.62 $255,916 - $293,339	23,244 Added 335.31%	30,176 $349,000
Q2 2023 Aug 11, 2023	SELL	$5.92 - $12.72 $40,865 - $87,806	-6,903 Reduced 49.9%	6,932 $79,000
Q1 2023 May 12, 2023	BUY	$6.74 - $9.44 $40,824 - $57,178	6,057 Added 77.87%	13,835 $95,000
Q4 2022 Feb 13, 2023	BUY	$8.05 - $11.58 $4,950 - $7,121	615 Added 8.59%	7,778 $67,000
Q3 2022 Nov 14, 2022	SELL	$3.31 - $13.06 $22,994 - $90,727	-6,947 Reduced 49.23%	7,163 $72,000
Q2 2022 Aug 12, 2022	BUY	$6.0 - $9.37 $64,860 - $101,289	10,810 Added 327.58%	14,110 $123,000
Q1 2022 May 12, 2022	BUY	$6.64 - $12.85 $21,912 - $42,405	3,300 New	3,300 $27,000
Q4 2021 Feb 10, 2022	SELL	$10.81 - $14.38 $17,144 - $22,806	-1,586 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$10.43 - $12.81 $16,541 - $20,316	1,586 New	1,586 $18,000

Others Institutions Holding IMTX

# of Institutions

Shares Held

92.5M

Call Options Held

313K

Put Options Held

377K

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $381M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account